NCT05914974Recruiting
Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
ICK-Gyn: Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
Source: ClinicalTrials.gov · Last updated 10 Feb 2026
Brief summary (registry, in English)
ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 13 Jun 2023
- Start date
- 11 Sept 2023
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- University Hospital Tuebingen
- Diseases
- Endometrial cancer, Cervical cancer, Ovarian cancer
- NCT number
- NCT05914974
What you commit to
- Study type: Observational
- Planned participants: 120
- From 11 Sept 2023 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- missing indication for ICI therapy in the experimental group
- any ICI therapy before inclusion into the trial
Other illness
- patients with advanced or metastatic endometrial or cervical cancer in the second or higher therapy line without indication to ICI therapy
- inadequate general condition (not fit for chemotherapy)
Other
- pregnant or lactating patients
Who the study is looking for
- women ≥ 18 years of age
- histologically proven metastatic gynecological malignancies irrespective of therapy line
- patients with advanced or metastatic gynecological malignancies must fulfill treatment requirements for ICI therapy in the experimental group
- planned ICI therapy in combination with palliative chemotherapy in the experimental group
- patients with advanced or metastatic gynecological malignancies that undergo chemotherapy without ICIs in the first therapy line in the control group
- written informed consent into ICK-Gyn
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Women's Health Coordinator of this site? Confirm its status | Tübingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.